Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer

BACKGROUND: MicroRNA (miRNA) is a small, non-coding RNA molecule which plays a role in the carcinogenesis and progression of cancers. Abnormal expression of miRNA in plasma has been found in some patients with malignant tumors. MATERIAL/METHODS: This study was conducted to investigate the expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Ling, Chen, Yifan, Su, Qiaoli, Tang, Xiaoju, Liang, Yasha, Che, Guowei, Luo, Fengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771099/
https://www.ncbi.nlm.nih.gov/pubmed/26918265
http://dx.doi.org/10.12659/MSM.897330
_version_ 1782418365103472640
author Sun, Ling
Chen, Yifan
Su, Qiaoli
Tang, Xiaoju
Liang, Yasha
Che, Guowei
Luo, Fengming
author_facet Sun, Ling
Chen, Yifan
Su, Qiaoli
Tang, Xiaoju
Liang, Yasha
Che, Guowei
Luo, Fengming
author_sort Sun, Ling
collection PubMed
description BACKGROUND: MicroRNA (miRNA) is a small, non-coding RNA molecule which plays a role in the carcinogenesis and progression of cancers. Abnormal expression of miRNA in plasma has been found in some patients with malignant tumors. MATERIAL/METHODS: This study was conducted to investigate the expression of miRNA-30a in plasma of patients with non-small cell lung cancer (NSCLC). The plasma miRNA-30a in 87 patients with NSCLC, 20 patients with benign lung diseases, and 76 healthy subjects were measured by real-time PCR. The diagnostic value of miRNA-30a in NSCLC was evaluated via the ROC curve method. RESULTS: Plasma miRNA-30a level was significantly higher in the NSCLC group compared with benign control and healthy control groups (P<0.01). No statistically significant difference was found in the expression level of miRNA-30a among various clinical pathologic features in NSCLC. ROC curve analysis showed that the specificity and sensitivity cut-off points were at 61.0% and 84.3% for NSCLC. The specificity and sensitivity values were 54.9% and 94.4%, respectively, in the analysis based on in-patients only. CONCLUSIONS: All these results suggest that plasma miRNA-30a measurement may be a novel and noninvasive method for NSCLC preliminary screening and differential diagnosis.
format Online
Article
Text
id pubmed-4771099
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-47710992016-03-14 Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer Sun, Ling Chen, Yifan Su, Qiaoli Tang, Xiaoju Liang, Yasha Che, Guowei Luo, Fengming Med Sci Monit Clinical Research BACKGROUND: MicroRNA (miRNA) is a small, non-coding RNA molecule which plays a role in the carcinogenesis and progression of cancers. Abnormal expression of miRNA in plasma has been found in some patients with malignant tumors. MATERIAL/METHODS: This study was conducted to investigate the expression of miRNA-30a in plasma of patients with non-small cell lung cancer (NSCLC). The plasma miRNA-30a in 87 patients with NSCLC, 20 patients with benign lung diseases, and 76 healthy subjects were measured by real-time PCR. The diagnostic value of miRNA-30a in NSCLC was evaluated via the ROC curve method. RESULTS: Plasma miRNA-30a level was significantly higher in the NSCLC group compared with benign control and healthy control groups (P<0.01). No statistically significant difference was found in the expression level of miRNA-30a among various clinical pathologic features in NSCLC. ROC curve analysis showed that the specificity and sensitivity cut-off points were at 61.0% and 84.3% for NSCLC. The specificity and sensitivity values were 54.9% and 94.4%, respectively, in the analysis based on in-patients only. CONCLUSIONS: All these results suggest that plasma miRNA-30a measurement may be a novel and noninvasive method for NSCLC preliminary screening and differential diagnosis. International Scientific Literature, Inc. 2016-02-26 /pmc/articles/PMC4771099/ /pubmed/26918265 http://dx.doi.org/10.12659/MSM.897330 Text en © Med Sci Monit, 2016 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
spellingShingle Clinical Research
Sun, Ling
Chen, Yifan
Su, Qiaoli
Tang, Xiaoju
Liang, Yasha
Che, Guowei
Luo, Fengming
Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer
title Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer
title_full Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer
title_fullStr Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer
title_full_unstemmed Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer
title_short Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer
title_sort increased plasma mirna-30a as a biomarker for non-small cell lung cancer
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771099/
https://www.ncbi.nlm.nih.gov/pubmed/26918265
http://dx.doi.org/10.12659/MSM.897330
work_keys_str_mv AT sunling increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer
AT chenyifan increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer
AT suqiaoli increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer
AT tangxiaoju increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer
AT liangyasha increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer
AT cheguowei increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer
AT luofengming increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer